# Magnus Medical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/magnus-medical

- Industry: Medical Devices & Equipment
- Headquarters: Burlingame, US
- Website: www.magnusmed.com
- Total disclosed funding: $25M
- Latest round: Series A (Oct 28, 2021)
- Investors on record: 2

## About

Magnus Medical focuses on developing innovative neuromodulation technologies, particularly its SAINT® Neuromodulation System, aimed at treating Major Depressive Disorder in adults who have not benefited from prior interventions.Founded in 2020 in Burlingame, US, Magnus Medical develops neuromodulation solutions to address mental health issues. The company was co-founded by Brandon Bentzley and Miguel Bunte. In October 2021, it successfully secured USD 25 mn in Series A funding, led by Jazz Venture Partners and Red Tree Venture Capital, bringing the total amount raised to USD 25 mn.Magnus Medical specializes in innovative neuromodulation technologies, primarily focusing on its flagship product, the SAINT® (Synchronized Antiphase Intermittent Neuromodulation Therapy) Neuromodulation System. This system is designed to treat Major Depressive Disorder (MDD) in adult patients who have not experienced satisfactory improvement from previous antidepressant medications. The SAINT therapy utilizes advanced algorithms in combination with structural and functional MRI to identify optimal therapy targets in the brain, delivering precise, non-invasive repetitive magnetic pulses to modify brain network activity associated with depression. Magnus Medical's client base includes prominent healthcare institutions such as the University of Arkansas for Medical Sciences and MUSC Health, as well as various clinics across California, underscoring its reach within the U.S. healthcare market. The company’s products are primarily marketed and sold within the United States, addressing the significant unmet needs in mental health treatment, particularly for patients with treatment-resistant depression.Magnus Medical's revenue model is structured around the provision of its SAINT Neuromodulation System to healthcare providers, including hospitals and clinics, for the treatment of Major Depressive Disorder. The company engages in direct sales to these medical facilities, allowing them to offer SAINT therapy as a treatment option for patients. The financial transactions typically involve the purchase of the neuromodulation equipment, along with associated training and ongoing support services. Additionally, Magnus Medical is actively involved in research collaborations and may establish partnerships with healthcare organizations to facilitate the implementation of its technology in clinical settings. These strategic alliances enhance the integration of SAINT therapy into existing treatment protocols and contribute to the company’s growth within the mental health sector.In October 2021, Magnus Medical raised USD 25 mn in Series A funding to enhance its technology into an integrated treatment system and support clinical trials focused on personalized, accelerated neuromodulation targeted at individuals suffering from severe depression. The company is planning to expand its product offerings and target new markets within the U.S. healthcare system, aiming to increase accessibility to its SAINT therapy and to meet the growing demand for effective mental health treatments.

## Funding rounds

- Series A, Oct 28, 2021, $25M — JAZZ Venture Partners, Red Tree Venture Capital

## Investors

- JAZZ Venture Partners (https://capitalatlas.ai/funds/jazz-venture-partners) — Series A
- Red Tree Venture Capital (https://capitalatlas.ai/funds/red-tree-venture-capital) — Series A